SNORA32: A Potential Drug Target and Biomarker (G692063)

Target Name: SNORA32

NCBI ID: G692063

SNORA32

Other Name(s): Small nucleolar RNA, H/ACA box 32 | small nucleolar RNA, H/ACA box 32 | ACA32

SNORA32: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA), also known as H/ACA box RNA, is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the well-known snRNAs is SNORA32, which is expressed in various tissues and cells and is involved in the regulation of gene expression.

SNORA32 is a 24.1 kilobase (kb) RNA molecule that contains 1,092 unique exons and 1,092 reverse transcription factor binding site (RISC) interactions. It is a part of the H/ACA box family of snRNAs, which are known to play a crucial role in the regulation of gene expression and are involved in various cellular processes, including DNA replication, transcription, and RNA splicing.

SNORA32 is expressed in various tissues and cells, including the brain, heart, liver, and kidney, and is involved in the regulation of gene expression in these tissues. For example, studies have shown that SNORA32 is expressed in the brain and is involved in the regulation of neuronal differentiation and synaptic plasticity. Additionally, it has been shown to be involved in the regulation of immune cell function and inflammation.

SNORA32 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that SNORA32 is expressed in various types of cancer, including breast, ovarian, and colorectal cancer, and is involved in the regulation of cell growth, apoptosis, and angiogenesis.

In addition to its role in disease, SNORA32 has also been shown to be a potential drug target. The H/ACA box is a conserved region that is involved in the regulation of various cellular processes, including gene expression and RNA binding, making it a potential target for small molecules. Additionally, the SNORA32 gene has been shown to be regulated by various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT signaling pathways, making it a potential target for drugs that can modulate these signaling pathways.

SNORA32 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that SNORA32 is expressed in the blood and urine of patients with various diseases, including cancer, cardiovascular disease, and neurological disorders. Additionally, the levels of SNORA32 have been shown to be associated with various disease outcomes, including survival in cancer patients.

In conclusion, SNORA32 is a well-known snRNA that is involved in the regulation of gene expression in various tissues and cells. Its expression is regulated by various signaling pathways and has been implicated in the development and progression of various diseases. Additionally, SNORA32 has also been shown to be a potential drug target and biomarker, making it a promising target for small molecules and diagnostic tools. Further research is needed to fully understand the role of SNORA32 in various cellular processes and its potential as a drug target and biomarker.

Protein Name: Small Nucleolar RNA, H/ACA Box 32

The "SNORA32 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA32 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets